Tests a GLP-1 drug and lifestyle education before fertility treatment in women with PCOS
Compares a GLP-1 drug with metformin in women with PCOS and obesity before fertility treatment.
Plain-language title generated from the registry record
Registry title: Effects of GLP-1RAs on Fertility Outcomes in Obese Women With PCOS
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with polycystic ovary syndrome (PCOS) and obesity who want to have a baby and plan fertility treatment.
- Age
- 18-40 years old
- Sex
- Women only
- Disease stage
- PCOS (Rotterdam criteria) with a BMI from 28 kg/m2 up to less than 35 kg/m2
- Earlier treatment
- Cannot have taken glucocorticoids or anti-androgen drugs in the last 3 months. Cannot have had more than 5% weight loss in the last 3 months.
Main reasons for not taking part
- Diseases or contraindications that make pregnancy or fertility treatment unsafe
- Abnormal liver or kidney function
- Severe heart and blood vessel disease, cancer or acute infection
- History of stomach or bowel surgery, or ongoing weight loss treatment
- Allergy to GLP-1 medicines
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Source: NCT07687667, who can take part
Where in China
- Peking University Third HospitalBeijing, ChinaContact: Liang LiangNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University Third Hospital
- Trial code
- NCT07687667
- Record updated
- 7 July 2026
- Original description
The goal of this clinical trial is to examine whether GLP1-RA and healthy lifestyle education in women with PCOS and obesity prior to fertility treatment improves live birth rate and other reproductive, maternal and perinatal outcomes compared to metformin plus healthy lifestyle education.Read full original descriptionShow less
Effects of GLP-1 Receptor Agonists Combined With Healthy Lifestyle Education Prior to Fertility Treatment on Reproductive Outcomes in Obese Women With Polycystic Ovary Syndrome
The goal of this clinical trial is to examine whether GLP1-RA and healthy lifestyle education in women with PCOS and obesity prior to fertility treatment improves live birth rate and other reproductive, maternal and perinatal outcomes compared to metformin plus healthy lifestyle education.
Inclusion: Women with a wish to conceive; Women with PCOS (Rotterdam criteria); 28 kg/m2≤BMI<35kg/m2; Age: 18-40 years old.
Exclusion: Women with diseases unsuitable for pregnancy or any other contraindications to infertility treatment Endocrine disorders; Abnormalities in liver and kidney function; Other medications such as glucocorticoids, anti-androgen drugs ;(spironolactone, cyproterone acetate, flutamide, etc.) within the last 3 months; Acute infections, severe cardiovascular disease, malignant tumors; Ongoing weight loss therapy (>5% weight loss in the last 3 months) or history of gastrointestinal surgery; Uterine abnormalities that may affect assisted reproductive outcomes, untreated hydrosalpinx Male azoospermia, severe oligozoospermia and asthenospermia, or patients receiving donor sperm treatment Chromosomal abnormalities, patients planning preimplantation genetic testing (PGT) or donor oocyte treatment History of recurrent miscarriag Allergic to or contraindicated for GLP-1 class medications.